Anticorresponding mutations of the KRAS and PTEN genes in human Endometrial Cancer

Oncology Reports

Volumn 7, Issue 3, 2000, Pages 567-570

  Ikeda, Takayuki ^a,b,c   Yoshinaga, Kousuke ^a   Suzuki, Akihiko ^a   Sakurada, Akira ^a   Ohmori, Hiroaki ^b   Horii, Akira ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Endometrial cancer; KRAS; PI3K Akt pathway; PTEN; RAS MAP kinase pathway

Indexed keywords

PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; ENDOMETRIUM TUMOR; FEMALE; GENETICS; HUMAN; ONCOGENE RAS; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; CARCINOMA, ADENOSQUAMOUS; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0034185044     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.3.567     Document Type: Article

References (21)

1. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics. CA Cancer J Clin 46: 5-27, 1996.
2. Enomoto T, Inoue M, Peratoni AO, Terakawa N, Tanizawa O and Rice JM: K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 50: 6139-6145, 1990.
3. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours (review). Int J Oncol 7: 413-421, 1995.
4. Varras MN, Koffa M, Koumantakis E, Ergazaki M, Protopapa E, Michalas S and Spandidos DA: ras gene mutations in human endometrial carcinoma. Oncology 53: 505-510, 1996.
5. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, Yin J, Wang S, Abraham JM, Souza RF, Smolinski KN, Meltzer SJ and Horii A: PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 17: 143-144, 1997.
6. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP and Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998.
7. Wu X, Senechal K, Neshat MS, Whang YE and Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinasc/Akt pathway. Proc Natl Acad Sci USA 95: 15587-15591, 1998.
8. Dahia PLM, Aguiar RCT, Alberta J, Kum JB, Caron S, Sill H, Marsh DJ, Ritz J, Freedman A, Stiles C and Eng C: PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 8: 185-193, 1999.
9. 1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96: 2110-2115, 1999.
10. Fogh J, Fogh JM and Orfeo T: One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59: 221-226, 1977.
11. Nishida M, Kasahara K, Oki A, Satoh T, Arai Y and Kubo T: Establishment of eighteen clones of Ishikawa cells. Hum Cell 9: 109-116, 1996.
12. Sambrook J, Fritsch EF and Maniatis T: Molecular cloning. A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
13. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA and Tsao MS: Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfccted by the E6E7 gene of human papilloma virus 16. Am J Pathol 148: 1763-1770, 1996.
14. Sakurada A, Suzuki A, Sato M, Yamakawa H, Orikasa K, Uyeno S, Ono T, Ohuchi N, Fujimura S and Horii A: Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary. Jpn J Cancer Res 88: 1025-1028, 1997.
15. Ouyang H, Furukawa T, Abe T, Kato Y and Horii A: The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res 4: 1071-1074, 1998.
16. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN and Srivastava S: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257, 1998.
17. Abe T, Ouyang H, Migita T, Kato Y, Kimura M, Shiiba K, Sunamura M, Matsuno S and Horii A: The somatic mutation frequency of the transforming growth factor ß receptor type II gene varies widely among different cancers with microsatellite instability. Eur J Surg Oncol 22: 474-477, 1996.
18. Sakurada A, Hamada H, Fukushige S, Yokoyama T, Yoshinaga K, Furukawa T, Sato S, Yajima A, Sato M, Fujimura S and Horii A: Adenovirus-mcdiated delivery of the PTEN gene inhibits cell growth by induction of apoptosis in endometrial cancer. Int J Oncol 15: 1069-1074, 1999.
19. Yoshinaga K, Sasano H, Furukawa T, Yamakawa H, Yuki M, Sato S, Yajima A and Horii A: The PTEN, BAX, and IGFIIR genes are mutated in endometrial atypical hyperplasia. Jpn J Cancer Res 89: 985-990, 1998.
20. Maxwell LG, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett CJ, Berchuck A and Futreal AP: Mutation of the PTEN tumor suppressor gene in endometrial hyperplasia. Cancer Res 58: 2500-2503, 1998.
21. Gu J, Tamura M and Yamada KM: Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 143: 1375-1383, 1998.